| Title: | Serum IL-1 beta predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy |
| Authors: | Kawagishi, Naoki Browse this author |
| Suda, Goki Browse this author →KAKEN DB |
| Sakamori, Ryotaro Browse this author |
| Matsui, Takeshi Browse this author |
| Onozawa, Masahiro Browse this author →KAKEN DB |
| Yang, Zijian Browse this author |
| Yoshida, Sonoe Browse this author |
| Ohara, Masatsugu Browse this author |
| Kimura, Megumi Browse this author |
| Kubo, Akinori Browse this author |
| Maehara, Osamu Browse this author |
| Fu, Qingjie Browse this author |
| Hosoda, Shunichi Browse this author |
| Tokuchi, Yoshimasa Browse this author |
| Suzuki, Kazuharu Browse this author |
| Nakai, Masato Browse this author |
| Sho, Takuya Browse this author |
| Morikawa, Kenichi Browse this author |
| Natsuizaka, Mitsuteru Browse this author |
| Ogawa, Koji Browse this author →KAKEN DB |
| Sakai, Hajime Browse this author |
| Ohnishi, Shunsuke Browse this author |
| Baba, Masaru Browse this author |
| Takehara, Tetsuo Browse this author |
| Sakamoto, Naoya Browse this author →KAKEN DB |
| Issue Date: | 7-Oct-2022 |
| Publisher: | Nature Portfolio |
| Journal Title: | Scientific reports |
| Volume: | 12 |
| Issue: | 1 |
| Start Page: | 16800 |
| Publisher DOI: | 10.1038/s41598-022-21315-z |
| Abstract: | De novo hepatitis B virus (HBV) reactivation occurs during direct-acting antiviral (DAA) treatment in hepatitis C virus (HCV)-infected patients with resolved HBV infection. We evaluated the predictive factors, mechanical insight, and differences of cytokine levels during anti-cancer/immunosuppressive and DAA. Eleven, 35, and 19 HCV-infected patients with previous HBV infection with HBV reactivation during DAA treatment, previous HBV infection without HBV reactivation during DAA treatment, and without HBV infection resolution receiving DAA treatment, respectively, were enrolled. Clinical data and baseline cytokine levels were analyzed. Low baseline serum interleukin (IL)-1 beta levels predicted de novo HBV reactivation during DAA treatment (odds ratio: 47.6, 95% confidence interval: 6.94-333.3). HCV-infected patients with the IL-1 beta gene single nucleotide polymorphism rs16944 AA allele had significantly higher IL-1 beta levels; no HCV-infected patient with the IL-1 beta AA allele experienced HBV reactivation during DAA treatment. Compared to HCV-infected patients with HBV infection resolution, non-HCV infected patients with or without HBV reactivation during anti-cancer/immunosuppressive therapy or bone marrow transplantation had remarkably lower baseline IL-1 beta levels. Low IL-1 beta levels were not associated with HBV reactivation. IL-1 beta levels before DAA for HCV-infected patients with resolved HBV infection could predict HBV reactivation during DAA treatment. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/87372 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
